Immune to Cancer: The CRI Blog
-
ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News
The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…
-
ASCO19 Day 4 Update: Kidney Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, and Melanoma
The fourth day at ASCO19 highlighted immunotherapy strategies for patients with kidney cancer, liver cancer, stomach cancer,…
-
ASCO19 Day 3 Update: Immunotherapy for Brain Cancer, Ovarian Cancer, Lung Cancer, and Patients with HIV
The third day at ASCO19 highlighted immunotherapy strategies for patients with brain cancer, ovarian cancer, lung cancer,…
-
ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies
The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…
-
ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy
The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…
-
ASCO19 Preview: Caring for Every Patient, Learning from Every Patient
Effective treatments and patient response are the focus of the world’s largest clinical cancer conference when it…
-
AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…
-
AACR19 Day 5 Update: Bispecific Antibodies, the Importance of “Helper” T Cells, and the Lloyd J. Old Award Lecture
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to…
-
AACR19 Day 4 Update: The Microbiome, Immunotherapy Biomarkers, and New Immune Targets
Day 4 of AACR19 explored the microbiome and its impact on cancer treatment, revealed insights into immunotherapy…